ASTM F2382 - 04(2010)

    Standard Test Method for Assessment of Intravascular Medical Device Materials on Partial Thromboplastin Time (PTT)

    Active Standard ASTM F2382 | Developed by Subcommittee: F04.16

    Book of Standards Volume: 13.01


      Format Pages Price  
    PDF 3 $38.00   ADD TO CART
    Hardcopy (shipping and handling) 3 $38.00   ADD TO CART


    Significance and Use

    The purpose of this test method is to determine the time citrated plasma exposed to medical materials takes to form a clot when exposed to a suspension of phospholipid particles and calcium chloride. In this test method, the test article is the activator. The PTT assay is a general screening test for medical materials ability to activate the intrinsic coagulation pathway. Material samples that show a shortened PTT are activators of the intrinsic coagulation pathway.

    Test samples that show a shortened PTT are activators of the intrinsic coagulation pathway. The results are reported as a percent of the negative control. The test article, reference materials, and controls are exposed to human plasma. The plasma is tested on a coagulation device. Each sample tube is assayed in duplicate.

    1. Scope

    1.1 This test method covers the screening of cardiovascular device materials for their ability to induce blood coagulation via the intrinsic coagulation pathway. This assay should be part of the hemocompatibility evaluation for devices and materials contacting human blood, as per ANSI/AAMI/ISO 10993-4.

    1.2 All safety policies and practices shall be observed during the performance of this test method.

    1.3 All plasma and any materials that had contact with plasma will be bagged in a biohazard bag, properly labeled with the contents, and disposed by appropriate means. The plasma should be handled at the Biosafety Level 2 as recommended in the Centers for Disease Control/National Institutes of Health Manual Biosafety in Microbiological Laboratories.

    1.4 The normal pooled human plasma must have tested negative for Hepatitis B (HBV) or Human Immunodeficiency (HIV) viruses. The plasmas should be treated like any patient plasma using universal precautions. The plasma should be handled at the Biosafety Level 2 as recommended in the Centers for Disease Control/National Institutes of Health Manual Biosafety in Microbiological Laboratories.

    1.5 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

    1.6 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.


    2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard.

    ANSI Standard

    ANSI/AAMI/ISO10993-4 Biological Evaluation of Medical Devices--Part 4: Selection of Tests for Interactions with Blood Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036, http://www.ansi.org.

    Other Document

    CentersforDiseaseCon 1999 Available from National Institute of Health (NIH), 9000 Rockville Pike, Bethesda, MD 20892.


    ICS Code

    ICS Number Code 11.100 (Laboratory medicine); 11.100.30 (Analysis of blood and urine)

    UNSPSC Code

    UNSPSC Code 42000000(Medical Equipment and Accessories and Supplies)


    DOI: 10.1520/F2382-04R10

    ASTM International is a member of CrossRef.

    ASTM F2382

    Citing ASTM Standards
    Back to Top